Sunday , September 22 2019
Home / unitedstates / The treatment of immune system shows a wider commitment to cancer

The treatment of immune system shows a wider commitment to cancer



ATLANTA (AP) – Treatment that helps the immune system fight dead blood cancer shows the promise of some precarious bodily bugs, hoping that this technique can be extended to more common body parts. the future.

The cure, called CAR-T, involves genetic change of some patients' own cells to help them recognize and attack cancer. Richard Carlstrand of Long Key, Florida, who had more than a year ago for mesothelioma, pale breast cancer of the lungs.

"We were going into unknown countries" to try this, he said, but now it doesn't show a cancer signal and "I couldn't be happier."

Results of his affairs and other issues were discussed at Sunday's conference for the Athena Research Inquiry in Atlanta.

The first CAR-T treatments were agreed in 2017 for some leukemias and lymphomas. After changing the laboratory, the cells in an updated security system will be returned to the patient through IV, who fixes them where there is cancer – in the blood.

But that technique doesn't work well if the long distance cells have to pass through blood flow to stores in the lungs, chest, colon, or other places.

"The adverse effects of negative pressure without allowing the cells to protect them," and not enough will affect it, says Dr Prasad Adusumilli from the Kettering Memorial Memorial Institute in New York .

More concerns are that the proteins on hard-bodied cells that provide those thermal targets are also found on normal cells at lower levels, so the treatment could also be harmful.

Adusumilli helped design a new CAR-T to try to avoid these problems and tested 19 mesothelioma patients and two other lung and breast cancer patients, who passed through to the pool. Around 150,000 patients a year in this case take up this situation.

The modified cells were just inserted into the chest where the bones were. A genetic safety puzzle was added so that a remedy could be given to destroy the cells if they had done damage.

After the treatment, one patient received surgery and radiation, and he does 20 months afterwards without further treatment. Fifteen others were good enough to start drug treatment which will significantly increase the immune system.

Eleven of the 15 were inspected sufficiently to record results. Two signs of cancer were returned for about a year, although one more returned again. Six people saw his bones falling. Three men were going about cancer.

There were no bad effects although some patients had low rates of blood and tiredness.

It is envisaged that contributions from the federal government and institutions that were paid for the work and increased scrutiny will be made. Sloan Kettering has licensed the medicine to Atara Biotherapeutics and he can get a payment from him, as Adusumilli may have.

A second study investigated the different treatment of CAR-T in 10 children and adults with advanced cervical cancer resulting in different soft tissues or soft bones. Unlike other Tsaris most commonly received just once, this was taken many times, up to 15 in the case of one patient, if there were signs it helped.

"From pulling one blood's blood we do a lot of the CAR-T cells and we freeze them" and give them through IV as necessary, "said Dr Shoba Navai from Baylor Medicine College. the Houston.

Two of the 10 patients who had all the symptoms of cancer disappear, one for 17 months and the other for nearly three years, so far. The disease was based in three others. Five people got worse against treatment.

Other impacts were as follows. The cure is safe "and we have early signs that this approach could help," said Navai.

A number of institutions and charities are paying for the work.

"These surveys show there is a way forward in hard illnesses" with CAR-T treatments, "said Dr Hugh Martin. Louis Weiner, director of Georgetown Lombardi's Center for Dedication and one of the conference leaders. It might promise that some cancer will occur in stomach, breast, colon, lungs and other areas, he said.

Cost is a big issue – about $ 400,000 is the current CAR-T treatments but they can be made for less than in research centers. Doctors say they hope that costs will come down when more market becomes available and find the way to wider use.

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

The Media Department for Health & Science is supported by a Science Education Department from Howard Hughes. The AP is fully dependent on all content.


Source link